Suprachoroidal Triamcinolone Acetonide Injection in Two Chorioretinal Diseases: One Year Results
Overview
- Phase
- Phase 2
- Intervention
- Triamcinolone Acetonide
- Conditions
- Central Serous Chorioretinopathy
- Sponsor
- Benha University
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Central macular thickness
- Last Updated
- 4 years ago
Overview
Brief Summary
Suprachoroidal injection is a safe way for intraocular drug delivery. It was used to treat various retinal conditions.
Detailed Description
Suprachoroidal triamcinolone acetonide injection is used to treat various retinal diseases, higher concentration of the injected material is found when the suprachoroidal space is used as an intraocular delivery pathway when compared to the conventional intravitreal pathway.
Investigators
Ahmed Abdelshafy
Assistant professor of Ophthalmology
Benha University
Eligibility Criteria
Inclusion Criteria
- •patients diagnosed as central serous chorioretinopathy and patients with cystoid macular edema due to irvine-gass syndrome after cataract surgery.
Exclusion Criteria
- •other retinal diseases that may affect CMT and final visual outcome.
- •Patients with dense corneal opacity.
Arms & Interventions
Central serous chorioretinopathy group
Cases with central serous chorioretinopathy (CSR) that will be injected with suprachoroidal triamcinolone acetonide.
Intervention: Triamcinolone Acetonide
Irvine-Gass Syndrome group
Cases with cystoid macular edema due to irvine-gass syndrome that will be injected with suprachoroidal triamcinolone acetonide
Intervention: Triamcinolone Acetonide
Outcomes
Primary Outcomes
Central macular thickness
Time Frame: Baseline and 12 months after injection.
Changes in central macular thickness (CMT) measured in millimeters (mm) by optical coherence tomography (OCT)
Secondary Outcomes
- Best corrected visual acuity(Baseline and 12 months after injection.)